
Company valuation, historical trends, and peer comparisons.
According to Damora Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 761.49M. This represents a change of 156.88% compared to the average of 296.43M of the last 4 quarters.
The mean historical Enterprise Value of Damora Therapeutics, Inc. over the last ten years is 81.36M. The current 761.49M Enterprise Value has changed 835.98% with respect to the historical average. Over the past ten years (40 quarters), DMRA's Enterprise Value was at its highest in in the June 2026 quarter at 1.05B. The Enterprise Value was at its lowest in in the December 2025 quarter at -219415337.31.
Average
81.36M
Median
6.37M
Minimum
-226193254.95
Maximum
370.53M
Discovering the peaks and valleys of Damora Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.97%
Maximum Annual Enterprise Value = 370.53M
Minimum Annual Increase = -118.62%
Minimum Annual Enterprise Value = -226193254.95
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | -226193254.95 | 2.97% |
| 2024 | -7361257.15 | 253.17% |
| 2023 | -2084322.00 | -24.52% |
| 2022 | -2761535.00 | -118.62% |
| 2021 | 14.83M | -90.33% |
| 2020 | 153.36M | -58.61% |
| 2019 | 370.53M | 5.70% |
The current Enterprise Value of Damora Therapeutics, Inc. (DMRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-78546278.03
5-year avg
-44714607.87
10-year avg
81.36M
Damora Therapeutics, Inc.’s Enterprise Value is less than Rigel Pharmaceuticals, Inc. (878.20M), less than Hemab Therapeutics Holdings, Inc. Common Stock (1.37B), less than Genmab A/S (28.14B), less than Geron Corporation (779.07M), less than Incyte Corporation (19.51B), greater than Keros Therapeutics, Inc. (-18231319.00), less than Disc Medicine, Inc. (2.82B), less than uniQure N.V. (1.21B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 878.20M | $899.06M | |
| 1.37B | $1.61B | |
| 28.14B | $26.93B | |
| 779.07M | $719.57M | |
| 19.51B | $23.45B | |
| -18231319.00 | $223.65M | |
| 2.82B | $2.86B | |
| 1.21B | $1.56B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Damora Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Damora Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Damora Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Damora Therapeutics, Inc. (DMRA)?
What is the 3-year average Enterprise Value for Damora Therapeutics, Inc. (DMRA)?
What is the 5-year average Enterprise Value for Damora Therapeutics, Inc. (DMRA)?
How does the current Enterprise Value for Damora Therapeutics, Inc. (DMRA) compare to its historical average?